09:31 AM EDT, 07/22/2024 (MT Newswires) -- Addex Therapeutics ( ADXN ) said Monday its partner J&J Innovative Medicine, formerly Janssen Pharmaceuticals, has said it has discontinued development of ADX71149 to treat epilepsy.

Addex said top-line phase 2 trial results disclosed on April 29 showed that administration of ADX71149 in people with "focal onset seizures with suboptimal response to levetiracetam or brivaracetam did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care."

The partnership between the companies will proceed, while the full results from the phase 2 trial of ADX71149 are analyzed, Addex said.

"We have had an excellent working relationship with Janssen for 20 years and will continue to work diligently to complete the analysis of the full phase 2 data set to elucidate all learnings from the study," said Addex Chief Executive Tim Dyer. "Once we have that information in hand, we anticipate a decision on the future of this asset."

Addex shares were down 2% in recent premarket activity.

Price: 7.99, Change: -0.16, Percent Change: -1.96